Explore

UCLA Health Study Links Common Pesticide Chlorpyrifos to Increased Parkinson's Risk

UCLA Health Study Links Common Pesticide Chlorpyrifos to Increased Parkinson's Risk

A new study from UCLA Health indicates that long-term exposure to the widely used pesticide chlorpyrifos may significantly increase the risk of Parkinson's disease. The research suggests that individuals with prolonged residential exposure to chlorpyrifos face more than 2.5 times the risk of developing Parkinson's compared to those not similarly exposed. This finding is based on data from the Parkinson’s Environment and Genes study, which analyzed information from 829 people with Parkinson's and 824 without the condition, correlating their residential and workplace histories with detailed pesticide application records in California. Laboratory experiments involving mice exposed to aerosolized chlorpyrifos for 11 weeks showed movement difficulties, loss of dopamine-producing neurons, brain inflammation, and abnormal alpha-synuclein accumulations, mirroring key features of human Parkinson's. Further studies using zebrafish revealed that chlorpyrifos disrupts autophagy, a cellular cleanup process, leading to ...

Harvard Medical School Researchers Link Low Lithium Levels to Alzheimer's, Show Promise in Mice

Harvard Medical School Researchers Link Low Lithium Levels to Alzheimer's, Show Promise in Mice

Researchers at Harvard Medical School, led by neuroscientist Bruce Yankner and first author Liviu Aron, have published findings in Nature indicating a potential link between lower lithium levels in the brain and Alzheimer's disease. Their study, conducted in collaboration with Rush University in Chicago, analyzed donated human brain tissue and found that lithium was the only one of 27 measured metals significantly lower in a brain region vulnerable to Alzheimer's in individuals with mild cognitive impairment and Alzheimer's disease. The team also observed that amyloid plaques, a hallmark of Alzheimer's, appeared to trap lithium, thereby reducing its availability to surrounding brain tissue. Subsequent experiments in mice demonstrated that reducing lithium levels led to more Alzheimer's-related brain changes and memory difficulties. Conversely, administering low doses of lithium orotate to these mice reduced some of these changes and improved their memory performance. This research suggests that a shortage ...

Biogen/Ionis Alzheimer's Drug Diranersen Receives UK Innovation Passport, Advances to Phase 3

Biogen/Ionis Alzheimer's Drug Diranersen Receives UK Innovation Passport, Advances to Phase 3

Biogen/Ionis's Alzheimer's drug, diranersen, a tau protein inhibitor, has been granted an Innovation Passport by the UK medicines regulator. This status is designed to accelerate NHS access to promising new medicines. Diranersen has completed its phase 2 CELIA trial, which, despite missing its primary endpoint, demonstrated signs of cognitive benefit. The drug works by shutting down the production of tau, a protein known to form neurofibrillary tangles, a hallmark of Alzheimer's disease. It is administered via intrathecal injection every three or six months. The Innovation Passport means the drug will undergo a fast-track review process under the innovative licensing and access pathway (ILAP), reducing review time to 150 days and providing additional support to the developer. This pathway also includes funding considerations through the involvement of NICE, the Scottish Medicines Consortium (SMC), and the All Wales Therapeutics and Toxicology Centre (AWTTC). The drug is now being prepared to advance into a...

New Research Reveals Distinct Tau Pathology in Early-Onset Alzheimer's, Suggesting Tailored Treatment Approaches

New Research Reveals Distinct Tau Pathology in Early-Onset Alzheimer's, Suggesting Tailored Treatment Approaches

A new study has revealed that early-onset Alzheimer's disease, which affects individuals under 65, exhibits a distinct and more aggressive tau pathology compared to late-onset Alzheimer's. Researchers compared 390 early-onset patients (average age 59) with 211 late-onset patients (average age 78), all with mild cognitive impairment or mild dementia and confirmed amyloid positivity. The study found that early-onset patients had higher initial levels of tau, spread across more brain regions, and accumulated tau twice as fast. This aggressive tau accumulation was more strongly linked to memory loss progression in younger patients. The findings suggest that early-onset Alzheimer's is not merely an earlier manifestation of the late-onset form but a distinct disease process, often presenting with non-memory-dominant symptoms like difficulties with language, vision, or executive functions.

Genentech and Roche to Present New Alzheimer's Disease Data at CTAD 2026, Highlighting Multi-pronged Therapeutic and Diagnostic Approaches

Genentech and Roche to Present New Alzheimer's Disease Data at CTAD 2026, Highlighting Multi-pronged Therapeutic and Diagnostic Approaches

Genentech, a member of the Roche Group, announced it will present new data from its Alzheimer's disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Congress in Boston from November 16-19, 2026. The presentations will cover advancements in both pharmaceuticals and diagnostics, emphasizing a comprehensive strategy to address Alzheimer's. Key pharmaceutical updates include new Phase Ib/IIa Brainshuttle™ AD study data for trontinemab, demonstrating rapid amyloid removal, and the design specifics for the Phase III PrevenTRON study of trontinemab in preclinical Alzheimer's. Additionally, Genentech and Roche are initiating a new Phase II clinical trial, TARBELA-AD, to evaluate the investigational oral NLRP3 inhibitor RG6434, which targets neuroinflammation. On the diagnostic front, Roche will present global clinical and health economic data for its Elecsys® pTau217 and Elecsys pTau181 blood tests, supporting earlier and more accurate diagnosis of Alzheimer's disease. These efforts reflect ...

Roche Initiates Phase II Clinical Trial for Alzheimer's Drug Targeting Neuroinflammation

Roche Initiates Phase II Clinical Trial for Alzheimer's Drug Targeting Neuroinflammation

Roche has announced the initiation of a new Phase II clinical trial, TARBELA-AD, to evaluate RG6434, an investigational oral NLRP3 inhibitor, for early symptomatic Alzheimer's disease. This study is part of Roche's broader strategy to address Alzheimer's by targeting various biological mechanisms, specifically focusing on neuroinflammation as a key driver of pathology in addition to amyloid aggregation. The announcement was made in anticipation of the 19th Clinical Trials on Alzheimer's Disease (CTAD) Congress in Boston, scheduled from November 16-19, 2026. According to Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer, this trial aims to test additional therapeutic hypotheses to potentially halt or prevent disease progression, complementing their ongoing trontinemab programs. Roche's diagnostics division is also expanding access to earlier and more accurate Alzheimer's diagnosis through its blood-based biomarker portfolio, including the FDA-cleared Elecsys pTau217 and Elecsys pTau181 tests.

BioVie to Present Positive Bezisterim Data for Parkinson's Disease at International Conference

BioVie to Present Positive Bezisterim Data for Parkinson's Disease at International Conference

BioVie Inc., a clinical-stage biopharmaceutical company, is scheduled to present new data on its investigational drug, bezisterim (NE3107), at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases in Barcelona, Spain, from March 16-20, 2027. The presentations will focus on exploratory analyses from the Phase 2 SUNRISE-PD trial, which evaluated bezisterim in 57 patients with early-stage Parkinson's disease. The study found that patients with higher systemic inflammation at baseline, defined by platelet counts above 230 × 10^9/L, showed significant improvements in both motor and non-motor symptoms of Parkinson's disease. Specifically, this subgroup experienced better scores in the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I (non-motor), Part III (motor), and Total Scores. The drug works by modulating key pathways involved in neuroinflammation and improving insulin sensitivity without suppressing the immune system.

Roche to Present New Alzheimer's Disease Data at CTAD 2026, Highlighting Multi-pronged Approach

Roche to Present New Alzheimer's Disease Data at CTAD 2026, Highlighting Multi-pronged Approach

Roche announced it will present new data from its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Congress in Boston, MA, from November 16–19, 2026. The company plans to showcase 16 accepted abstracts, including two scientific symposia and two oral presentations. A key highlight is the initiation of a new Phase II clinical trial, TARBELA-AD, which will evaluate RG6434, an investigational oral NLRP3 inhibitor, for early symptomatic Alzheimer’s disease. This trial signifies Roche's strategy to target neuroinflammation, alongside its ongoing efforts to address amyloid aggregation with candidates like trontinemab. Dr. Levi Garraway, Roche’s Chief Medical Officer, emphasized the need for multifaceted strategies to combat the complexity of Alzheimer's. Additionally, Roche's diagnostics division will present data on its blood-based biomarker portfolio, including the FDA-cleared Elecsys pTau217 and Elecsys pTau181 tests, aimed at enabling earlier and more accurate diagnosis.

Acadia Pharmaceuticals to Present Remlifanserin Data at Alzheimer's Disease Conference

Acadia Pharmaceuticals to Present Remlifanserin Data at Alzheimer's Disease Conference

Acadia Pharmaceuticals Inc. announced it will present two data presentations related to Alzheimer's disease psychosis (ADP) and its investigational drug, remlifanserin, at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. The presentations will include findings from the Phase 2 portion of the ongoing RADIANT clinical trial program, which evaluates remlifanserin in patients with ADP. An oral presentation will detail the efficacy and safety of remlifanserin, while a poster presentation will examine biomarker heterogeneity among patients meeting clinical criteria for ADP. Remlifanserin is a novel, highly selective 5-HT2A receptor inverse agonist being developed to treat psychosis associated with Alzheimer's disease and Lewy body dementia. Currently, there is no FDA-approved drug specifically for the treatment of Alzheimer's disease psychosis.

New Scoring System Developed to Identify Hidden Sleep Issues in Advanced Parkinson's Disease Patients

New Scoring System Developed to Identify Hidden Sleep Issues in Advanced Parkinson's Disease Patients

A new sleep scoring system has been developed to better track sleep disruptions in individuals with advanced Parkinson's disease, according to a study published in Sleep Medicine. Standard monitoring methods often fail to detect unique disruptions in brain activity caused by the disease. Researchers identified five new stages of abnormal sleep and wakefulness that are not present in healthy individuals or those in the early stages of Parkinson's. These disturbances are closely linked to older age, cognitive decline, and fluctuating motor symptoms. The study involved 15 adults with Parkinson's and five age-matched healthy controls. Overnight video-polysomnography was used to record brain waves, eye movements, muscle activity, and breathing. The new method detected these abnormal sleep stages in 12 out of 15 Parkinson's patients, accounting for a significant portion of their recording time. The three remaining patients, who were in early stages without cognitive impairment or motor fluctuations, could be ful...

Milken Institute Highlights Critical Gaps in Menopause and Brain Health Research

Milken Institute Highlights Critical Gaps in Menopause and Brain Health Research

The Milken Institute Women’s Health Network has released a brief titled 'Menopause and Brain Health: What Women Need to Know,' which underscores significant research gaps concerning menopause, particularly its impact on brain health. The report emphasizes that while menopause is primarily seen as a reproductive transition, it is also a crucial brain health transition. Hormonal changes during this period interact with sleep, mood, hot flashes, stress, and overall health, influencing how women think, feel, and function. The brief notes that cognitive symptoms like memory difficulties, concentration issues, and 'brain fog' are real and can affect daily life, work, and confidence, though they are generally subtle and distinct from more serious cognitive conditions. The Milken Institute aims to improve awareness, care, and support for women experiencing these changes.

FDA's New Rare Disease Framework Initiative Hailed as 'Quantum Leap' for Patient Community

FDA's New Rare Disease Framework Initiative Hailed as 'Quantum Leap' for Patient Community

The U.S. Food and Drug Administration (FDA) has launched a new Rare Disease Framework Initiative, which is being widely recognized as a significant advancement for the rare disease community. This initiative follows years of advocacy from patients, caregivers, and organizations like The LAM Foundation, who have consistently shared their experiences and needs. The framework aims to address critical challenges inherent in rare diseases, such as small patient populations, limited understanding of disease progression, and difficulties in measuring treatment effectiveness. The LAM Foundation has expressed strong support for this new effort, highlighting its potential to foster greater collaboration among patients, researchers, clinicians, and regulators. The organization plans to actively participate in the public comment process, contributing insights from its community of women and families affected by rare conditions. This initiative signifies a pivotal moment where patient voices are being formally integrat...